Waterhouse DN - Search Results

1

Preparation, characterization, and biological analysis of liposomal formulations of vincristine.

Waterhouse DN, Madden TD, Cullis PR, Bally MB, Mayer LD, Webb MS. Waterhouse DN, et al. Methods Enzymol. 2005;391:40-57. doi: 10.1016/S0076-6879(05)91002-1. Methods Enzymol. 2005. PMID: 15721373

2

The liposomal formulation of doxorubicin.

Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB. Abraham SA, et al. Among authors: waterhouse dn. Methods Enzymol. 2005;391:71-97. doi: 10.1016/S0076-6879(05)91004-5. Methods Enzymol. 2005. PMID: 15721375

3

A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention.

Ramsay E, Alnajim J, Anantha M, Zastre J, Yan H, Webb M, Waterhouse D, Bally M. Ramsay E, et al. Eur J Pharm Biopharm. 2008 Mar;68(3):607-17. doi: 10.1016/j.ejpb.2007.08.011. Epub 2007 Sep 2. Eur J Pharm Biopharm. 2008. PMID: 17904831

4

Drug-drug interactions arising from the use of liposomal vincristine in combination with other anticancer drugs.

Waterhouse DN, Dos Santos N, Mayer LD, Bally MB. Waterhouse DN, et al. Pharm Res. 2001 Sep;18(9):1331-5. doi: 10.1023/a:1013050330608. Pharm Res. 2001. PMID: 11683249 No abstract available.

5

A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles.

Waterhouse DN, Tardi PG, Mayer LD, Bally MB. Waterhouse DN, et al. Drug Saf. 2001;24(12):903-20. doi: 10.2165/00002018-200124120-00004. Drug Saf. 2001. PMID: 11735647 Review.

6

Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model.

Waterhouse DN, Gelmon KA, Masin D, Bally MB. Waterhouse DN, et al. J Exp Ther Oncol. 2003 Sep-Oct;3(5):261-71. doi: 10.1111/j.1533-869x.2003.01099.x. J Exp Ther Oncol. 2003. PMID: 14696623

7

Pharmacodynamic behavior of liposomal antisense oligonucleotides targeting Her-2/neu and vascular endothelial growth factor in an ascitic MDA435/LCC6 human breast cancer model.

Waterhouse DN, Dragowska WH, Gelmon KA, Mayer LD, Bally MB. Waterhouse DN, et al. Cancer Biol Ther. 2004 Feb;3(2):197-204. Epub 2004 Feb 1. Cancer Biol Ther. 2004. PMID: 14726684

8

Trastuzumab and liposomal Doxorubicin in the treatment of mcf-7 xenograft tumor-bearing mice: combination does not affect drug serum levels.

Waterhouse DN, Denyssevych T, Hudon N, Chia S, Gelmon KA, Bally MB. Waterhouse DN, et al. Pharm Res. 2005 Jun;22(6):915-22. doi: 10.1007/s11095-005-4586-z. Epub 2005 Jun 8. Pharm Res. 2005. PMID: 15948035

9

Lipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy.

Waterhouse DN, Yapp D, Verreault M, Anantha M, Sutherland B, Bally MB. Waterhouse DN, et al. Nanomedicine (Lond). 2011 Nov;6(9):1645-54. doi: 10.2217/nnm.11.140. Nanomedicine (Lond). 2011. PMID: 22077466

10

Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities.

Waterhouse DN, Sutherland BW, Santos ND, Masin D, Osooly M, Strutt D, Ostlund C, Anantha M, Harasym N, Manisali I, Wehbe M, Bally MB, Webb MS. Waterhouse DN, et al. Invest New Drugs. 2014 Dec;32(6):1071-82. doi: 10.1007/s10637-014-0138-x. Epub 2014 Jul 27. Invest New Drugs. 2014. PMID: 25064374 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

39 results

Search Page